Search - tctmd.com

Displaying 21 - 40 of 468

Sort: Relevancy | Date

Presentation TCT 2017

Underutilization of TAVR in Minority Populations: Scope, Etiologies, and Possible Solutions

Presenter: Eberhard Grube, James B. Hermiller Jr., Oluseun Alli

November 01, 2017

Presentation TCT 2017

Shared Decision-making is an Essential Component of the Modern-era Heart Team: Rationale and Integration with TAVR Clinical Practice

Presenter: Eberhard Grube, James B. Hermiller Jr., Megan Coylewright

November 01, 2017

Presentation TCT 2017

How to Avoid and Treat Complications Associated With Transcatheter PV Therapy

Presenter: Elchanan Bruckheimer, Doff B. McElhinney

November 01, 2017

Presentation TCT 2017

Counterpoint More than Two TAVR Devices on Your Shelf is Unnecessary!

Presenter: Haim Danenberg

November 01, 2017

Presentation TCT 2017

30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Valve Disease Secondary to Mitral Annular Calcification or Failed Annuloplasty Rings

Presenter: Mayra Guerrero

November 01, 2017

Presentation TCT 2017

Point A Multi-Device Lesion-Specific Approach is Preferred!

Presenter: Michael J. Reardon

November 01, 2017

Presentation TCT 2017

Current Results of Transcatheter PV Therapy: Melody and Sapien

Presenter: Elchanan Bruckheimer, Doff B. McElhinney, Thomas K. Jones

November 01, 2017

Presentation TCT 2017

RV-PA Conduit Dysfunction: The History of Transcatheter PV Therapy

Presenter: Elchanan Bruckheimer, Doff B. McElhinney, Michael J. Mullen

November 01, 2017

Presentation TCT 2017

Commentary II At What Point Does the Minimalist Strategy Become Ludicrous?

Presenter: Martin B. Leon

November 01, 2017

Presentation TCT 2017

Commentary I Insights From the 3M Trial

Presenter: David A. Wood

November 01, 2017

Presentation TCT 2017

Counterpoint A Customized Approach, Including General Anesthesia and TEE, Optimizes Patient Outcomes!

Presenter: Omar K. Khalique

November 01, 2017

Presentation TCT 2017

Point TAVR Without General Anesthesia and Without TEE is now the Default Strategy!

Presenter: Ganesh Manoharan

November 01, 2017

Presentation TCT 2017

Counterpoint Clinical Trial Results are Inconclusive and Systematic Use of Cerebral Protection During TVR is Unwarranted!

Presenter: Duane S. Pinto

November 01, 2017

Presentation TCT 2017

Point A Balanced Look at ALL the Data Favors Cerebral Protection in ALL TAVR Patients!

Presenter: Saif Anwaruddin

November 01, 2017

Presentation TCT 2017

Transcatheter TR Solution 8: GATE Valve

Presenter: Francesco Maisano, Jason H. Rogers, Jose Luis Navia

November 01, 2017

Presentation TCT 2017

TAVR in Patients With Severe CKD: Diagnostic Workup, Valve Sizing, and Procedural and Post-Procedure Management

Presenter: Nirat Beohar

November 01, 2017

Presentation TCT 2017

Transcatheter TR Solution 7: TRAIPTA

Presenter: Francesco Maisano, Jason H. Rogers, Toby Rogers

November 01, 2017

Presentation TCT 2017

Managing AS Patients With Atrial Fibrillation in TAVR Patients Pharmacotherapy Considerations and LAAC Possibilities (WATCH-TAVR Trial)

Presenter: Samir R. Kapadia

November 01, 2017

Presentation TCT 2017

Transcatheter TR Solution 6: Millipede

Presenter: Francesco Maisano, Jason H. Rogers, Steven F. Bolling

November 01, 2017

Presentation TCT 2017

Transcatheter TR Solution 5: Cardioband

Presenter: Francesco Maisano, Jason H. Rogers, Ralph Stephan von Bardeleben

November 01, 2017

Advertisement

Underutilization of TAVR in Minority Populations: Scope, Etiologies, and Possible Solutions

Shared Decision-making is an Essential Component of the Modern-era Heart Team: Rationale and Integration with TAVR Clinical Practice

How to Avoid and Treat Complications Associated With Transcatheter PV Therapy

Counterpoint More than Two TAVR Devices on Your Shelf is Unnecessary!

30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Valve Disease Secondary to Mitral Annular Calcification or Failed Annuloplasty Rings

Point A Multi-Device Lesion-Specific Approach is Preferred!

Current Results of Transcatheter PV Therapy: Melody and Sapien

RV-PA Conduit Dysfunction: The History of Transcatheter PV Therapy

Commentary II At What Point Does the Minimalist Strategy Become Ludicrous?

Commentary I Insights From the 3M Trial

Counterpoint A Customized Approach, Including General Anesthesia and TEE, Optimizes Patient Outcomes!

Point TAVR Without General Anesthesia and Without TEE is now the Default Strategy!

Counterpoint Clinical Trial Results are Inconclusive and Systematic Use of Cerebral Protection During TVR is Unwarranted!

Point A Balanced Look at ALL the Data Favors Cerebral Protection in ALL TAVR Patients!

Transcatheter TR Solution 8: GATE Valve

TAVR in Patients With Severe CKD: Diagnostic Workup, Valve Sizing, and Procedural and Post-Procedure Management

Transcatheter TR Solution 7: TRAIPTA

Managing AS Patients With Atrial Fibrillation in TAVR Patients Pharmacotherapy Considerations and LAAC Possibilities (WATCH-TAVR Trial)

Transcatheter TR Solution 6: Millipede

Transcatheter TR Solution 5: Cardioband

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content